Osteoporosis
Endocrine-disrupting chemicals may reduce bone density among children and young adults
Exposure to higher levels of endocrine-disrupting chemicals may hinder bone development for children, adolescents and young adults, according to study findings published in Environmental Research.
FDA adds boxed warning of increased severe hypocalcemia risk for denosumab
The FDA has added a boxed warning for denosumab to advise patients with advanced chronic kidney disease of an increased risk for severe hypocalcemia, according to an FDA drug safety communication.
Machine learning predicts osteoporosis in patients with rheumatoid arthritis
Machine learning algorithms can be effective in predicting osteoporosis among patients with rheumatoid arthritis, as well as identifying new predictive factors, according to data published in Nature Scientific Reports.
Attention to nutrition, exercise can combat weight gain, other symptoms in menopause
Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Elizabeth Ward, MS, RDN, and Hillary Wright, MEd, RDN, LDN, about women’s nutrition and exercise needs as they age.
Less than 25% of patients with cirrhosis, low bone density are treated for osteoporosis
Patients with cirrhosis are less frequently screened for osteoporosis compared with the general population, and less than 25% with low bone density actually receive treatment, according to research in Alimentary Pharmacology & Therapeutics.
Polygenic risk score incorporating rare variants does not improve fracture prediction
The identification of rare genetic variants that influence bone mineral density did not significantly improve fracture risk screening among a large group of adults, according to data published in Journal of Bone and Mineral Research.
Romosozumab superior to denosumab for improving spine bone mineral density at 12 months
SAN DIEGO — Romosozumab is superior to denosumab for increasing bone mineral density in the spine at 12 months among chronic glucocorticoid users with osteoporosis at high fracture risk, according to data presented at ACR Convergence 2023.
Teva gains FDA approval for generic form of Forteo for certain patients with osteoporosis
Teva Pharmaceuticals announced FDA approval of a generic version of Forteo in the U.S. for certain women and men with osteoporosis, according to a company press release.
Review: Menopause apps need osteoporosis content, expert insight and simplicity
Current menopause smartphone apps require more information on osteoporosis, expert input and better quality, functionality and simplicity of use and understanding for the general public, researchers reported.
Bone density decreases when stopping, never using menopausal hormone therapy
Postmenopausal women who stopped or never used hormone therapy over a 5-year period experienced a loss in bone density, whereas bone density was maintained for those who continued treatment, researchers reported in Menopause.